Scarica l'app Stockscreener
4.24
1.19%
0.05
Nervgen Pharma Corp Borsa (NGEN) Ultime notizie
NervGen Pharma initiated with a Buy at Lucid Capital - TipRanks
NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference - Bitget
NGEN Options Volatility — NASDAQ:NGEN - TradingView — Track All Markets
NGEN Options Chain — NASDAQ:NGEN - TradingView — Track All Markets
Is NervGen Pharma still undervalued? - Cantech Letter
Lobbying Update: $50,000 of NERVGEN PHARMA CORP. lobbying was just disclosed - Quiver Quantitative
NGEN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia - Sahm
NervGen receives FDA alignment on Phase 3 trial for tetraplegia By Investing.com - Investing.com South Africa
NervGen Pharma Says Phase 3 Chronic Tetraplegia Study Design Aligns With US FDA - marketscreener.com
NervGen Wins FDA Alignment for Phase 3 RESTORE Trial in Chronic Tetraplegia - TipRanks
NervGen receives FDA alignment on Phase 3 trial for tetraplegia - Investing.com
NervGen Pharma aligns with FDA on RESTORE study following End-of-Phase 2 meeting - TipRanks
NervGen Pharma Corp. announces that patient enrollment for its Phase 1B/2a CONNECT-SCI clinical trial targeting individuals with quadriplegia due to subacute spinal cord injury is nearing completion. - Bitget
Nervgen Pharma announces successful end-of-phase 2 meeting and FDA alignment on Restore, a phase 3 registrational study of NVG-291 for chronic tetraplegia - marketscreener.com
Nervgen Pharma Announces Successful End-Of-Phase 2 Meeting And FDA Alignment On Restore, A Phase 3 Registrational Study Of Nvg-291 For Chronic Tetraplegia - TradingView — Track All Markets
Analysts Offer Insights on Healthcare Companies: Milestone Scientific (MLSS) and NervGen Pharma (NGEN) - The Globe and Mail
The Rise of 6 Emerging Therapies in a Critical Spinal Cord Injury Market Void | DelveInsight - The Manila Times
NervGen Pharma Corp. Stock Chart | NASDAQ: NGEN Stock Price - Bitget
This analyst loves NervGen Pharma - Cantech Letter
NervGen appoints regulatory and patient advocacy executives - Investing.com
NervGen Maps Path to Phase 3 as NVG-291 Data Strengthen Neuroreparative Ambitions - TipRanks
NervGen Pharma reports full year 2025 financial results and provides business updates - MarketScreener
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates - Bitget
NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Spinal Cord Injury Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment By DelveInsight | StemCyte, NervGen Pharma, VA Office of Research and Development, Kessler - Barchart
NervGen Pharma Corp.(TSXV: NGEN) dropped from S&P/TSX Venture Composite Index - marketscreener.com
NervGen Pharma (NGEN.US) Income Statements, Balance Sheet & Cashflow - Longbridge
NervGen Pharma Stock Quote, Share Price, News and Analysis - Longbridge
NervGen Pharma: I See Promise, But The Clock Is Ticking (Rating Downgrade) (NASDAQ:NGEN) - Seeking Alpha
NGEN.CA Stock Price, Quote & Chart | NERVGEN PHARMA CORP (TSX-V:NGEN) - ChartMill
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange - Sahm
NervGen Pharma to delist shares from TSX - TipRanks
NervGen Pharma (NGEN) to Voluntarily Delist from TSX Venture Exc - GuruFocus
NervGen Pharma to Delist from TSX Venture Exchange, Keep Nasdaq Listing as NVG-291 Advances - TipRanks
NervGen appoints regulatory and patient advocacy executives By Investing.com - Investing.com Nigeria
NervGen Pharma proposes amendment to warrant terms - MSN
NervGen Pharma price target raised to C$6.75 from C$5 at Stifel - TipRanks
Nanogen appoints Ruff as Chief Regulatory Affairs Officer, McSherry as SVP - TipRanks
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP of Patient Advocacy - geneonline.com
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs - The Manila Times
NervGen Pharma CFO to Retire as Company Advances Late-Stage SCI Program - TipRanks
Spinal Cord Injury Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals By DelveInsight | StemCyte, NervGen Pharma, VA Office of Research and Development - StreetInsider
NervGen Pharma (NGEN) Stock Analysis Report | Financials & Insights - Benzinga Japan
NGENFNervgen Pharma Corp Latest Stock News & Market Updates - Stock Titan
NervGen Pharma to Participate at Upcoming Investor Conferences - The Manila Times
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):